03 July 2024 : Clinical Research
Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-Cell Lymphoma
Jie Wang1ABCDEFG*, Ming Yang2CD, Sheng Chen2CEF, Hongbo Zhu1AB, Zhirong Zhang1CDDOI: 10.12659/MSM.943551
Med Sci Monit 2024; 30:e943551
Abstract
BACKGROUND: Gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) is the most common histological subtype of extra-nodal DLBCL, but the risk factors, prognostic biomarkers, histopathological classifications, and treatment strategies have not had significant progress. Emerging evidence shows that cystatin SN (CST1) is involved in tumor progression in several cancer types, but its role in GI-DLBCL has not been revealed.
MATERIAL AND METHODS: We established a cohort consisting of 84 patients with GI-DLBCL who underwent surgical resection. The expression of CST1 in the cohort was investigated by immunohistochemistry, which divided the patients into subgroups with low or high expression of CST1. Moreover, the CST1 expression in GI-DLBCL tissues or adjacent GI tissues were compared with RT-qPCR. The correlation between CST1 expression and clinicopathological factors was analyzed with the chi-square test. The prognostic significance of CST1 was estimated by univariate and multivariate analysis, and statistical significance was analyzed with the log-rank test.
RESULTS: CST1 was aberrantly upregulated in GI-DLBCL tissues compared with in non-tumor GI tissues. High expression of CST1 indicated poor prognosis of GI-DLBCL (P=0.012), and CST1 can be regarded as an independent prognostic biomarker of GI-DLBCL (hazard ratio=3.07). In our study, serum lactate dehydrogenase (P=0.002), performance status (P=0.003), Lugano stage (P=0.002), and International Prognostic Index (P=0.001) were also prognostic factors of GI-DLBCL.
CONCLUSIONS: CST1 is an independent prognostic biomarker of GI-DLBCL, indicating unfavorable prognosis. Our results suggested that CST1 detection can be a promising method to stratify high-risk patients and guide individual treatment.
Keywords: Biomarkers, Tumor, Gastrointestinal Neoplasms, Lymphoma, Non-Hodgkin, Prognosis, CST1 Protein, Human
Editorial
01 July 2024 : Editorial
Editorial: The Global Threats of Increasing Antimicrobial Resistance Require New Approaches to Drug Development, Including Molecular Antimicrobial AdjuvantsDOI: 10.12659/MSM.945583
Med Sci Monit 2024; 30:e945583
In Press
Review article
Noncontact Sensors for Vital Signs Measurement: A Narrative ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.944913
Clinical Research
Burden and Patterns of Electric Scooter-Related Injuries: Insights From 2 Polish Emergency DepartmentsMed Sci Monit In Press; DOI: 10.12659/MSM.944448
Clinical Research
Identification of RESP18 Gene Mutations Linked to Hereditary Non-Syndromic Cleft Lip and Palate in a Southe...Med Sci Monit In Press; DOI: 10.12659/MSM.944294
Clinical Research
Edible Bite Force Sensor: A Novel Approach to Measuring Bite Force in Biomedical and Dental ApplicationsMed Sci Monit In Press; DOI: 10.12659/MSM.944050
Most Viewed Current Articles
17 Jan 2024 : Review article 2,789,521
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research 1,575,853
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 690,678
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial 50,536
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952